Novartis Pauses Cell Therapy Trials After Three Deaths

Novartis has paused studies of an experimental autoimmune cell therapy after three patient deaths. The company halted the clinical trials following the deaths. In separate news, Novartis shares climbed after its pill met goals in multiple sclerosis trials. The company also announced study success for its MS drug.